EP0768082B1 - Stabile, gelatinüberzogene Aspirintabletten - Google Patents

Stabile, gelatinüberzogene Aspirintabletten Download PDF

Info

Publication number
EP0768082B1
EP0768082B1 EP96305519A EP96305519A EP0768082B1 EP 0768082 B1 EP0768082 B1 EP 0768082B1 EP 96305519 A EP96305519 A EP 96305519A EP 96305519 A EP96305519 A EP 96305519A EP 0768082 B1 EP0768082 B1 EP 0768082B1
Authority
EP
European Patent Office
Prior art keywords
coating
dosage unit
pepsin
aspirin
gelatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96305519A
Other languages
English (en)
French (fr)
Other versions
EP0768082A1 (de
Inventor
Mahesh Patell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0768082A1 publication Critical patent/EP0768082A1/de
Application granted granted Critical
Publication of EP0768082B1 publication Critical patent/EP0768082B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Definitions

  • This invention pertains to stabilized pharmaceutical compositions, more particularly gelatin coated pharmaceutically active dosage units containing a therapeutically active ingredient which is subject to hydrolysis on storage as a result of moisture in the air or in one or more of the components of the dosage unit. It is especially concerned with the stabilization of analgesics such as gelatin coated aspirin tablets.
  • the stabilizing agent is a proteolytic enzyme.
  • the presently preferred stabilizing agent is pepsin. This proteolytic enzyme has been found to be a useful stabilizing agent at remarkably low concentrations.
  • Aspirin (TRADE MARK), or salicylic acid acetate is a well known therapeutic agent which has been employed for many years as an analgesic as well as for its antipyretic and anti-inflammatory properties.
  • Pepsin is a proteolytic enzyme which is the principal digestive enzyme of gastric juice. It controls the degradation of proteins to proteoses and peptones. Pepsin is obtained from hogs' stomachs by maceration in water acidulated with hydrochloric acid under frequent stirring for several days followed by salting out with sodium chloride or equivalent reagent. The pepsin is precipitated and floats to the surface from which it is recovered, purified and dried.
  • Pepsin is available as commercial preparations mixed with lactose. Such preparations have activities of from about 3000 to about 20,000 units. A pepsin preparation with an activity of 3000 digests not less than 3000 nor more than 3500 times its weight of coagulated egg albumin. As stated above, pepsin is the presently preferred proteolytic enzyme for use in this invention.
  • FSA free salicylic acid
  • gelatin coated aspirin A second problem with gelatin coated aspirin is that during storage FSA produced by moisture catalyzed hydrolysis of the aspirin denatures the gelatin making it insoluble in water. As a result, the therapeutic agent is not released.
  • the principal source of moisture in gelatin coated products is in the gelatin film.
  • Pepsin has been mentioned previously in connection with aspirin formulations. However, it has not been utilized to stabilize aspirin products in the same manner or, in fact, in any manner which is suggestive of the use described and claimed herein.
  • Metcalf in U.S. Patents 650,760 and 671,804 describes the combination of pepsin and gelatin to assist in the digestion of the capsule shell or coatings of pills and tablets.
  • U.S. Patent 3,322,626 mentions compositions for the treatment of acne in which the therapeutic agent is mixed with pepsin or other hydrolytic enzyme.
  • the tablet may be coated.
  • pepsin are capable of stabilizing aspirin compositions against hydrolytic decomposition thus rendering these compositions “stable”.
  • the present invention provides a pharmaceutical dosage unit comprising:
  • the aspirin dosage forms or units of this invention comprise a solid core containing a therapeutically effective amount of aspirin.
  • a first protective coating on the core.
  • This coating contains a quantity of pepsin which is effective to stabilize the aspirin for a period of 13 weeks at 40°C and 75% relative humidity or for 26 weeks at 35°C and 75% relative humidity.
  • the coating comprises pepsin dispersed with a film forming polymer of the type commonly used in the trade for coating pharmaceutical preparations.
  • the polymer is preferably, chemically inert, i.e., it does not react appreciably with any of the components of its environment including, for example aspirin, pepsin, gelatin, moisture or any of the fillers used in the preparations.
  • Those skilled in the art will be well aware of such film forming materials.
  • the second coating on the dosage form is gelatin of the type normally employed for such purposes.
  • the products of the invention may contain, in addition to a therapeutically effective quantity of aspirin, at least one of a wide variety of other therapeutic components normally employed with aspirin.
  • these include, for example, nasal decongestants (e.g. pseudoephedrine hydrochloride), antihistamines (e.g. chlorpheniramine maleate), sleep aids (e.g. diphenydramine dihydrogen citrate), analgesics (e.g. acetaminophen), antitussives (e.g. dextromethorpan hydrobromide), caffeine, or antacids such as magnesium oxide, calcium carbonate and the like.
  • nasal decongestants e.g. pseudoephedrine hydrochloride
  • antihistamines e.g. chlorpheniramine maleate
  • sleep aids e.g. diphenydramine dihydrogen citrate
  • analgesics e.g. acetaminophen
  • a therapeutically effective amount of aspirin for the dosage forms of this invention will vary with the proposed utility and with the regimen for administration.
  • the process of administration is oral, but a treatment dosage unit may be administered as one dosage unit, or as several dosage units over a period of time. Accordingly, the amount of aspirin in specific dosage units is not critical.
  • Therapeutically effective amounts may vary over a wide range, typically from about 80 to about 700 milligrams per coated tablet or other dosage unit.
  • the presently preferred film former for the first coat is Methocel or methyl cellulose.
  • Other typically useful pharmaceutically acceptable film formers are hydroxy propyl cellulose, hydroxy propyl methyl cellulose, carboxy methyl cellulose, sodium carboxy methyl cellulose, polyvinyl pyrrolidone, methacrylic ethers (Eudragit available from Rhom Pharma), ethyl cellulose, methyl cellulose and pseudo latex ethocel systems (available from FMC).
  • Other useful materials will be known to the skilled artisan or can be identified by reference to Remington's Pharmaceutical Sciences, 18th Edition.
  • Gelatin is a well known coating material used in pharmaceutical practice. It is derived by acid or basic hydrolysis from the collagen of skin, tendons, ligaments and bones. It is available commercially in many forms. The principal commercial forms are acid bone gelatin and lime bone gelatin. These are presently preferred because of their ready availability. However, any pharmaceutically acceptable gelatin suitable for human administration may be employed in the invention. All forms of gelatin are water soluble, hygroscopic proteins. Their water content varies appreciably. When first layered on a tablet substrate, they are in the form of a flexible sheet with a water content of about 30% by weight based on the weight of the gelatin on a wet basis. When dried for commercial distribution of the tablets, the water content is about 6% by weight on the same basis.
  • compositions of this invention While aspirin is normally the principal therapeutically active ingredient in the compositions of this invention, other therapeutic components such as those identified above may be employed in the mixture. Additionally the composition may contain other inert ingredients often employed in such compositions including disintegrants such as corn starch, cellulose (e.g., microcrystalline cellulose), Primogel, AC-DI-SOL, sodium carboxymethyl cellulose, Veegum HV, bentonite and others well known to the skilled artisan; lubricants such as magnesium, zinc or calcium stearates, stearic acid, mineral oil, waxes or sodium lauryl sulfate; fillers such as lactose, dicalcium phosphate, calcium sulfate, mannitol, kaolin, starch, etc; and buffering agents, typically magnesium, sodium or calcium carbonates.
  • disintegrants such as corn starch, cellulose (e.g., microcrystalline cellulose), Primogel, AC-DI-SOL, sodium carboxymethyl cellulose,
  • the products of this invention can be produced by conventional procedures well known to those skilled in the art.
  • the solid core may be produced, for example by compression on a tablet press.
  • the first coating is typically applied by spray coating an aqueous solution or suspension containing the pepsin and film coating agent and, optionally, a plasticizer, while the cores are tumbled in a coating pan.
  • the coating process is carried out at an elevated temperature so that the water contained in the coating solution or suspension flashes off when the solution or suspension is sprayed onto the tumbled cores.
  • the presently preferred procedure for forming the gelatin coating is the enrobing procedure described in U.S. Patent 5,146,730, the entire disclosure of which is incorporated herein by reference. Briefly, the tablet is enrobed in a gelatin coating formed by application of respective layers of elastic gelatin film to opposite sides of the coated inner core. The applied gelatin layers conform tightly to the tablet surface, bond securely thereto and are sealed together in an essentially edge to edge manner at a seal line which extends around the tablet. Other equivalent procedures are known and can be employed.
  • the amount of pepsin which will be effective to achieve stabilization will vary with the activity of the pepsin selected and with the amount of aspirin to be stabilized.
  • the optimum quantity of pepsin of a selected activity to achieve stabilization of dosage units containing a therapeutically effective amount of aspirin can be readily ascertained by a few simple tests or by calculation based on the teachings of this disclosure, especially the following description for the optimum amounts of pepsin in a gelatin coated tablet containing 674 mg of aspirin. If the inner core weighs more or less than 674 mg, the amount of pepsin utilized for stabilization will vary accordingly while maintaining the same weight ratios of the various components.
  • the amount of pepsin having an activity of 3000 will be from about 0.2% to about 0.3% by weight.
  • Such coated tablets are then enrobed in gelatin using for example, the enrobing process of U.S. Patent 5,146,730.
  • the total amount of gelatin normally applied is from about 90 to 150 mg. per tablet, the average weight being about 114 mg, per tablet including the moisture content.
  • the tablets therefore are coated with from about 11% to about 20% gelatin.
  • Each of 100 tablets will contain about 0.2% to about 0.3% pepsin.
  • a Typical tablet of the invention the central core of which weighs about 674 mg and contains principally aspirin, may be coated with 5.055 mg of a mixture containing 2.5275 mg of pepsin and 5.5275 mg of methocel.
  • This example shows the efficacy of pepsin for the stabilization of aspirin.
  • Tablets were prepared by coating an inner solid core of aspirin using an aqueous mixture containing 7.5% pepsin and 7.5% methocel. The amount of dried coating on the core was 0.75%. The tablet was then enrobed in gelatin to provide a final tablet weighing about 795 mg coated with 15% gelatin.
  • the tablets were then packaged in groups of 20 and 40 tablets, each package containing one standard dessicant.
  • the aspirin tablets were then subjected to accelerated stability tests under the conditions shown in the following table. At selected intervals the tablets were tested to determine the amount of FSA formed. The stabilizing action of pepsin is readily apparent from the table. These tablets could be labeled as stable for two years.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

  1. Pharmazeutische Dosierungseinheit umfassend :
    a) einen festen Kern, der eine therapeutisch wirksame Menge eines Arzneimittels enthält, das beim Abbau Säure oder ein anderes Produkt freisetzt, das Gelatine denaturiert;
    b) einen ersten Überzug auf dem Kern, der ein pharmazeutisch verträgliches filmbildendes Polymer und eine stabilisierende Menge eines proteolytischen Enzyms wie Pepsin umfasst; und
    c) einen Gelatineüberzug, der den ersten Überzug umhüllt.
  2. Dosierungseinheit nach Anspruch 1, worin das proteolytische Enzym Pepsin ist.
  3. Salicylsäureacetat-haltige Dosierungseinheit umfassend:
    a) einen festen Kern, der eine therapeutisch wirksame Menge Aspirin enthält;
    b) einen ersten Überzug auf dem Kern, der ein pharmazeutisch verträgliches filmbildendes Polymer und eine zur Stabilisierung des Aspirins für eine Zeitdauer von wenigstens 13 Wochen bei Lagerung der Dosierungseinheit bei 40 °C und 75 % relativer Feuchte oder 26 Wochen bei Lagerung bei 35 °C und 75 % relativer Feuchte wirksame Menge Pepsin umfasst; und
    c) einen Gelatineüberzug, der den ersten Überzug umhüllt.
  4. Dosierungseinheit nach Anspruch 2 oder 3, dadurch gekennzeichnet, dass das Pepsin eine Aktivität von 3000 bis 20000 Einheiten aufweist.
  5. Dosierungseinheit nach Anspruch 2 oder 3, dadurch gekennzeichnet, dass das Pepsin eine Aktivität von etwa 3000 Einheiten aufweist.
  6. Dosierungseinheit nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass das filmbildende Polymer Methocel ist.
  7. Dosierungseinheit nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass der Kern 80 bis 700 mg Salicylsäureacetat enthält.
  8. Dosierungseinheit nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass der Kern Salicylsäureacetat zusammen mit wenigstens einem anderen Heilmittel enthält.
  9. Dosierungseinheit nach Anspruch 8, dadurch gekennzeichnet, dass das Heilmittel unter Nasendekongestionsmitteln, Antihistaminika, Schlafmitteln, Analgetika, Antitussiva, Antazida und Koffein ausgewählt ist.
  10. Dosierungseinheit nach Anspruch 8, dadurch gekennzeichnet, dass das Heilmittel Acetaminophen oder Koffein ist.
  11. Verfahren zur Stabilisierung einer pharmazeutischen Dosierungseinheit umfassend einen festen Kern, der eine therapeutisch wirksame Menge eines Arzneimittels enthält, das beim Abbau Säure oder ein Produkt freisetzt, das Gelatine denaturiert, einen ersten Überzug auf dem Kern, der ein pharmazeutisch verträgliches Filmpolymer umfasst, und einen Gelatineüberzug, der den ersten Überzug umhüllt, wobei man den Kern außerdem mit einer zur Verbesserung der Arzneimittelstabilität wirksamen Menge Pepsin überzieht.
  12. Verfahren zur Stabilisierung einer Aspirin-Dosierungseinheit in der Weise, dass das darin enthaltene Aspirin für eine Zeitdauer von wenigstens 13 Wochen bei Lagerung der Dosierungseinheit bei 40 °C und 75 % relativer Feuchte oder 26 Wochen bei Lagerung bei 35 °C und 75 % relativer Feuchte stabil ist, wobei die Dosierungseinheit einen festen Kern, der eine therapeutisch wirksame Menge Salicylsäureacetat enthält, einen ersten Überzug auf dem Kern, der ein pharmazeutisch verträgliches Filmpolymer umfasst und einen Gelatineüberzug, der den ersten Überzug umhüllt, umfasst, wobei man den Kern außerdem mit einer zur Verbesserung der Aspirin-Stabilität für die genannte Zeitdauer wirksamen Menge Pepsin überzieht.
  13. Verfahren nach Anspruch 12, dadurch gekennzeichnet, dass das Pepsin in den ersten Überzug eingebaut ist.
EP96305519A 1995-07-28 1996-07-26 Stabile, gelatinüberzogene Aspirintabletten Expired - Lifetime EP0768082B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/508,647 US5750145A (en) 1995-07-28 1995-07-28 Stable gelatin coated aspirin tablets
US508647 1995-07-28

Publications (2)

Publication Number Publication Date
EP0768082A1 EP0768082A1 (de) 1997-04-16
EP0768082B1 true EP0768082B1 (de) 2001-11-14

Family

ID=24023517

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96305519A Expired - Lifetime EP0768082B1 (de) 1995-07-28 1996-07-26 Stabile, gelatinüberzogene Aspirintabletten

Country Status (9)

Country Link
US (1) US5750145A (de)
EP (1) EP0768082B1 (de)
AT (1) ATE208614T1 (de)
CA (1) CA2180810C (de)
DE (1) DE69616936T2 (de)
DK (1) DK0768082T3 (de)
ES (1) ES2164215T3 (de)
HK (1) HK1004470A1 (de)
PT (1) PT768082E (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274162B1 (en) 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
DE10245212B4 (de) * 2002-09-27 2008-01-03 Ivoclar Vivadent Ag Verwendung säurehaltiger Mittel zur Desensibilisierung von Zähnen
CA2566384C (en) * 2004-05-28 2010-08-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
CA2617164A1 (en) * 2005-08-01 2007-02-08 Alpharma Inc. Alcohol resistant pharmaceutical formulations
AU2006317530B2 (en) * 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
EP2340814A3 (de) 2009-12-31 2012-05-23 Ranbaxy Laboratories Limited Stabile Aspirintablette und Herstellungsverfahren dafür
US8327856B2 (en) * 2010-03-30 2012-12-11 Celanese Acetate Llc Environmentally degradable cigarette filter
WO2012034167A1 (en) * 2010-09-13 2012-03-22 Smartvet Pty Ltd System for oral delivery of an agent to an animal
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
JP2019519487A (ja) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US671804A (en) * 1899-12-02 1901-04-09 Frederick H Metcalf Coated pill, &c.
US650760A (en) * 1899-12-02 1900-05-29 Frederick H Metcalf Gelatin capsule.
US1879762A (en) * 1931-02-12 1932-09-27 Squibb & Sons Inc Protection of autoxidizable materials
US3493652A (en) * 1962-09-14 1970-02-03 Charles W Hartman Controlled release medicament
JPS5758615A (en) * 1980-09-26 1982-04-08 Nippon Soda Co Ltd Film agnent and its preparation
US4900559A (en) * 1985-12-12 1990-02-13 Briston-Myers Company Stabilized enteric coated aspirin granules and process of preparation
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4716042A (en) * 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets

Also Published As

Publication number Publication date
CA2180810A1 (en) 1997-01-29
PT768082E (pt) 2002-05-31
DE69616936D1 (de) 2001-12-20
DK0768082T3 (da) 2002-03-18
ES2164215T3 (es) 2002-02-16
HK1004470A1 (en) 1998-11-27
ATE208614T1 (de) 2001-11-15
US5750145A (en) 1998-05-12
DE69616936T2 (de) 2002-07-18
CA2180810C (en) 2009-10-13
EP0768082A1 (de) 1997-04-16

Similar Documents

Publication Publication Date Title
EP0768082B1 (de) Stabile, gelatinüberzogene Aspirintabletten
US5753254A (en) Therapeutic agents containing thyroid hormones
JP2503340B2 (ja) 反芻動物への経口投与のための作用物質調合物及び反芻動物の滋養物又は獣医薬供給法
US6106861A (en) Multiparticulate tablet disintegrating in less than 40 seconds in the mouth
US4650664A (en) Oral mopidamol preparation
US4892738A (en) Sustained-release granular pharmaceutical preparations
CA2238344A1 (en) Fast-melt solid dosage form and method of making same
IL106580A (en) Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof
KR20030023860A (ko) 맛 차폐용 코팅 조성물
LT3664B (en) Sustained release drug formation containing a tramadol salt
LT5045B (lt) Prolonguoto išsiskyrimo granulės, turinčios stavudino
GB2105590A (en) Flotable controlled release preparations
CZ291999B6 (cs) Tableta pro léčbu migrény a způsob její přípravy
EP0181650A1 (de) Pressdragierte dispergierbare Tabletten
JP3170855B2 (ja) イブプロフェン含有解熱鎮痛剤
JPH08503964A (ja) 食餌療法の低コレステロール血組成物
US3991180A (en) Stabilization of internally administered pancreatic lipase
CA3055116C (en) Orodispersible tablet containing burlulipase and pharmaceutical composition produced therefrom
US6544557B2 (en) Effervescent tablet compositions
US4716042A (en) Stabilized coated aspirin tablets
JP2002316928A (ja) コーティング錠及びコーティング錠のはがれを防止する方法
WO2000025754A2 (en) Solid oral dosage forms containing alginic acid and famotidine
EP0879050B1 (de) Captopriltabletten
CA1321752C (en) Products containing gallopamil and prazosin
US4049791A (en) Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 960803;LT PAYMENT 960803;LV PAYMENT 960803;SI PAYMENT 960803

17P Request for examination filed

Effective date: 19970925

17Q First examination report despatched

Effective date: 19990105

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19960803;LT PAYMENT 19960803;LV PAYMENT 19960803;SI PAYMENT 19960803

LTIE Lt: invalidation of european patent or patent extension
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20011114

REF Corresponds to:

Ref document number: 208614

Country of ref document: AT

Date of ref document: 20011115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69616936

Country of ref document: DE

Date of ref document: 20011220

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2164215

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20020400349

Country of ref document: GR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20020211

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: NOVARTIS AG

Free format text: BRISTOL-MYERS SQUIBB COMPANY#345 PARK AVENUE#NEW YORK, N.Y. 10154 (US) -TRANSFER TO- NOVARTIS AG#LICHTSTRASSE 35#4056 BASEL (CH)

NLS Nl: assignments of ep-patents

Owner name: NOVARTIS AG

Effective date: 20060329

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070725

Year of fee payment: 12

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080726

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20090629

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20090804

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20100707

Year of fee payment: 15

Ref country code: IE

Payment date: 20100712

Year of fee payment: 15

Ref country code: ES

Payment date: 20100813

Year of fee payment: 15

Ref country code: CH

Payment date: 20100714

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20100708

Year of fee payment: 15

Ref country code: IT

Payment date: 20100723

Year of fee payment: 15

Ref country code: FR

Payment date: 20100805

Year of fee payment: 15

Ref country code: FI

Payment date: 20100712

Year of fee payment: 15

Ref country code: DE

Payment date: 20100721

Year of fee payment: 15

Ref country code: AT

Payment date: 20100712

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20100615

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20100713

Year of fee payment: 15

Ref country code: DK

Payment date: 20100712

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20100714

Year of fee payment: 15

BERE Be: lapsed

Owner name: *NOVARTIS A.G.

Effective date: 20110731

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120126

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120201

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20020400349

Country of ref document: GR

Effective date: 20120202

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 208614

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110726

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120330

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110801

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120201

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69616936

Country of ref document: DE

Effective date: 20120201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120126

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120202

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110726

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120201

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110726

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100726

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20121122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110727